- Last interim results for the pharmacodynamics (PD) study of the 3-‐month implant form reveal the study has exceeded the limits of 8 non-‐responsive patients set for the trial.
- The detailed results of this study, still ongoing, will remain completely blinded. Final results are expected end H1 2016 and the full report in the following few weeks.
- In parallel, the pharmacokinetics (PK) study, is still in progress. On the basis of PD and PK results, expected end H2, Mithra will review the next steps of Zoreline® 3 month implant development.
- The pharmacokinetics and pharmacodynamics studies for the 1-‐month form of Zoreline® which is focused on Women’s Health (endometriosis, fibrosis and breast cancer) are expected to begin in summer 2016.
Liège, Belgium, 31 March 2016 – Regulated Information – The development process of Zoreline® program which started in 2015 is composed of 3 steps.